The Process

Through our years of experience we have continually refined and improved our processes in working with our GP Partners and believe our latest model offers greatest value to both GPs and patients. 

1. Synexus is commissioned to deliver a new clinical study and obtains all appropriate ethical approval.

2. Synexus Clinical Relations Team liaises with partner practices to obtain agreement to participate in the clinical study.

3. Practices that agree to participate in the study are allocated an Interface Clinical Pharmacist to undertake the patient mailing. The Interface Clinical Pharmacist team are experts on all GP clinical systems and can ensure the patient mailing process will not impede daily practice activities. For those of you that used to work with us, this means that you will no longer need to undertake the mailing yourself, and the voucher payment scheme will no longer exist, as any extra work will be completed for you.

4. Patient confidentiality is maintained at all times. The pharmacists are bound by the Royal Pharmaceutical Society Code of Ethics and Practice, Data Protection Act 1998, and where appropriate the ABPI Code of Practice.

5. Patient choice is integral to the process, after all it is the patient who decides to contact Synexus directly should they be interested in study participation.

6. If a patient is accepted onto the study, the GP will be required to complete a short medical questionnaire for which an appropriate payment is made (current BMA rates). Our experience has been that approximately 3% of patients contacted progress onto a clinical study.

7. Any relevant test results are communicated with the GP practice.